Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.45 +0.08 (+0.33%)
Streaming Delayed Price Updated: 2:31 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
10 Best Defensive Stocks To Invest In 2023
A defensive stock is a stock that demonstrates relatively stable performance regardless of the current state of the economy. Defensive stocks are less prone to the economic cycle of expansions and... 
Via Talk Markets
Topics Economy
Exposures Economy
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why the growth investor may take a look at NASDAQ:CPRX.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article. 
Via Chartmill
5 Analysts Have This to Say About Catalyst Pharmaceuticals
Via Benzinga
Where Catalyst Pharmaceuticals Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
Via Benzinga
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
Study Reveals LEMS Often Goes Undiagnosed in U.S. Patients with Small Cell Lung Cancer 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts. 
Via InvestorPlace
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
The Company to Host a Conference Call and Webcast on August 10, 2023, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential. 
Via InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on... 
Via Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The 7 Best Stocks Under $15 to Buy in June 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount. 
Via InvestorPlace
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
When evaluating investments, it helps to keep quarterly performance in context. 
Via The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81. 
Via Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones. 
Via Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits. 
Via Investor's Business Daily
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS